The use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has seen an exponential surge among pediatric patients. A critical increase in prescriptions for children aged 8 to 11 is raising alarms among medical professionals due to a lack of nutritional supervision and potential risks to physical and psychological development during early growth stages.
Science is moving forward with inspiring results that promise a healthier future. From the first-ever targeted treatment for a rare neurological condition to significant strides in managing pediatric weight and fighting lung cancer, these medical milestones represent a leap toward better quality of life for thousands of patients worldwide.
A critical medical emergency in Australia has sent shockwaves through the international health community. A patient suffered a severe esophageal tear after using a counterfeit weight-loss drug sold as Retatrutide. The Therapeutic Goods Administration (TGA) discovered the product contained dangerously high doses of Semaglutide, highlighting the life-threatening risks of buying peptides through social media and unregulated markets.
Losing weight is an achievement, but keeping it off is an even greater challenge. At the XVII Argentine Nutrition Conference, specialists will unveil the keys to sustaining weight loss and avoiding the dreaded 'yo-yo effect'.
A recent study suggests that GLP-1 medications like semaglutide could slow biological aging. Researchers found that their use reduces inflammation and visceral fat, though they warn it's not a fountain of youth and should be used with caution.
